Remember Me
Or use your Academic/Social account:


Or use your Academic/Social account:


You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.


Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message


Verify Password:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Richens, Joanna L; Vere, Kelly-Ann; Light, Roger A; Soria, Daniele; Garibaldi, Jonathan; Smith, A David; Warden, Donald; Wilcock, Gordon; Bajaj, Nin; Morgan, Kevin; O’Shea, Paul (2014)
Publisher: e-Century Publishing Corporation
Languages: English
Types: Article
Subjects: Original Article
Previous mass spectrometry analysis of cerebrospinal fluid (CSF) has allowed the identification of a panel of molecular markers that are associated with Alzheimer’s disease (AD). The panel comprises Amyloid beta, Apolipoprotein E, Fibrinogen alpha chain precursor, Keratin type I cytoskeletal 9, Serum albumin precursor, SPARC-like 1 protein and Tetranectin. Here we report the development and implementation of immunoassays to measure the abundance and diagnostic capacity of these putative biomarkers in matched lumbar CSF and blood plasma samples taken in life from individuals confirmed at post-mortem as suffering from AD (n = 10) and from screened ‘cognitively healthy’ subjects (n = 18). The inflammatory components of Alzheimer’s disease were also investigated. Employment of supervised learning techniques permitted examination of the interrelated expression patterns of the putative biomarkers and identified inflammatory components, resulting in biomarker panels with a diagnostic accuracy of 87.5% and 86.7% for the plasma and CSF datasets respectively. This is extremely important as it offers an ideal high-throughput and relatively inexpensive population screening approach. It appears possible to determine the presence or absence of AD based on our biomarker panel and it seems likely that a cheap and rapid blood test for AD is feasible.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • [19] [20] Prvulovic D and Hampel H. Amyloid beta (Abeta) and phospho-tau (p-tau) as diagnostic biomarkers in Alzheimer's disease. Clin Chem Lab Med 2011; 49: 367- 374.
    • Ewers M, Mielke MM and Hampel H. Blood-based biomarkers of microvascular pathology in Alzheimer's disease. Exp Gerontol 2010; 45: 75-79.
    • Alzheimers Dement 2008; 4: 38-48.
    • Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M, Mulugeta E, Rosen E, Aarsland D, Visser PJ, Schroder J, Marcusson J, de Leon M, Hampel H, Scheltens P, Pirttila T, Wallin A, Jonhagen ME, Minthon L, Winblad B and Blennow K. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 2009; 302: 385-393.
    • Schneider P, Hampel H and Buerger K. Biological marker candidates of Alzheimer's disease in blood, plasma, and serum. CNS Neurosci Ther 2009; 15: 358-374.
    • Cerebrospinal fluid levels of beta-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry 2012; 69: 98-106.
    • Vafadar-Isfahani B, Ball G, Coveney C, Lemetre C, Boocock D, Minthon L, Hansson O, Miles AK, Janciauskiene SM, Warden D, Smith AD, Wilcock G, Kalsheker N, Rees R, Matharoo-Ball B and Morgan K. Identification of SPARC-like 1 Protein as Part of a Biomarker Panel for Alzheimer's Disease in Cerebrospinal Fluid. J Alzheimers Dis 2012; 28: 625-636.
    • Thambisetty M, Simmons A, Velayudhan L, Hye A, Campbell J, Zhang Y, Wahlund LO, Westman E, Kinsey A, Guntert A, Proitsi P, Powell J, Causevic M, Killick R, Lunnon K, Lynham S, Broadstock M, Choudhry F, Howlett DR, Williams RJ, Sharp SI, Mitchelmore C, Tunnard C, Leung R, Foy C, O'Brien D, Breen G, Furney SJ, Ward M, Kloszewska I, Mecocci P, Soininen H, Tsolaki M, Vellas B, Hodges A, Murphy DG, Parkins S, Richardson JC, Resnick SM, Ferrucci L, Wong DF, Zhou Y, Muehlboeck S, Evans A, Francis PT, Spenger C and Lovestone S. Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch Gen Psychiatry 2010; 67: 739-748.
    • Non-linear relationships of cerebrospinal fluid biomarker levels with cognitive function: an observational study. Alzheimers Res Ther 2011; 3: 5.
    • [21] Quinlan JR. C4.5: programs for machine learning. Morgan Kaufmann Publishers Inc., 1993.
    • [22] John GH and Langley P. Estimating continuous distributions in Bayesian classifiers. Proceedings of the Eleventh conference on Uncertainty in artificial intelligence 1995
    • [23] Haykin S. Neural Networks: A Comprehensive Foundation. Prentice Hall PTR, 1998.
    • [24] Gutierrez C and Schiff R. HER2: biology, detection, and clinical implications. Arch Pathol Lab Med 2011; 135: 55-62.
    • [25] Lim LS and Sherin K. Screening for prostate cancer in U.S. men ACPM position statement on preventive practice. Am J Prev Med 2008; 34: 164-170.
    • [26] de Bono JS and Ashworth A. Translating cancer research into targeted therapeutics. Nature 2010; 467: 543-549.
    • [27] Richens JL, Morgan K and O'Shea P. Reverse engineering of Alzheimer's disease based on biomarker pathways analysis. Neurobiol Aging In press;
    • [28] Anderson NL and Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 2002; 1: 845-867.
    • [29] Yuan X, Russell T, Wood G and Desiderio DM. Analysis of the human lumbar cerebrospinal fluid proteome. Electrophoresis 2002; 23: 1185-1196.
    • [30] Richens JL, Lunt EA, Sanger D, McKenzie G and O'Shea P. Avoiding nonspecific interactions in studies of the plasma proteome: practical solutions to prevention of nonspecific interactions for label-free detection of low-abundance plasma proteins. J Proteome Res 2009; 8: 5103-5110.
    • [31] Chalbot S, Zetterberg H, Blennow K, Fladby T, Andreasen N, Grundke-Iqbal I and Iqbal K. Blood-cerebrospinal fluid barrier permeability in Alzheimer's disease. J Alzheimers Dis 2011; 25: 505-515.
    • [32] Morgan K. The three new pathways leading to Alzheimer's disease. Neuropathol Appl Neurobiol 2011; 37: 353-357.
    • [33] Jones L, Holmans PA, Hamshere ML, Harold D, Moskvina V, Ivanov D, Pocklington A, Abraham R, Hollingworth P, Sims R, Gerrish A, Pahwa JS, Jones N, Stretton A, Morgan AR, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Love S, Kehoe PG, Mead S, Fox N, Rossor M, Collinge J, Maier W, Jessen F, Schurmann B, Heun R, Kolsch H, van den Bussche H, Heuser I, Peters O, Kornhuber J, Wiltfang J, Dichgans M, Frolich L, Hampel H, Hull M, Rujescu D, Goate AM, Kauwe JS, Cruchaga C, Nowotny P, Morris JC, Mayo K, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Al-Chalabi A, Shaw CE, Singleton AB, Guerreiro R, Muhleisen TW, Nothen MM, Moebus S, Jockel KH, Klopp N, Wichmann HE, Ruther
    • [43] Lau CP, Poon RT, Cheung ST, Yu WC and Fan ST. SPARC and Hevin expression correlate with tumour angiogenesis in hepatocellular carcinoma. J Pathol 2006; 210: 459-468.
    • [44] Mencalha AL, Levinsphul A, Deterling LC, Pizzatti L and Abdelhay E. SPARC-like1 mRNA is overexpressed in human uterine leiomyoma. Mol Med Report 2008; 1: 571- 574.
    • [45] Hammack BN, Fung KY, Hunsucker SW, Duncan MW, Burgoon MP, Owens GP and Gilden DH. Proteomic analysis of multiple sclerosis cerebrospinal fluid. Mult Scler 2004; 10: 245-260.
    • [46] Yin GN, Lee HW, Cho JY and Suk K. Neuronal pentraxin receptor in cerebrospinal fluid as a potential biomarker for neurodegenerative diseases. Brain Res 2009; 1265: 158-170.
    • [47] Carmeliet P and De Strooper B. Alzheimer's disease: A breach in the blood-brain barrier. Nature 2012; 485: 451-452.
    • [48] Lee KS, Chung JH, Choi TK, Suh SY, Oh BH and Hong CH. Peripheral cytokines and chemokines in Alzheimer's disease. Dement Geriatr Cogn Disord 2009; 28: 281- 287.
    • [49] Hu WT, Chen-Plotkin A, Arnold SE, Grossman M, Clark CM, Shaw LM, Pickering E, Kuhn M, Chen Y, McCluskey L, Elman L, Karlawish J, Hurtig HI, Siderowf A, Lee VM, Soares H and Trojanowski JQ. Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment. Acta Neuropathol 2010; 119: 669-678.
    • [50] Choi C, Jeong JH, Jang JS, Choi K, Lee J, Kwon J, Choi KG, Lee JS and Kang SW. Multiplex analysis of cytokines in the serum and cerebrospinal fluid of patients with Alzheimer's disease by color-coded bead technology. J Clin Neurol 2008; 4: 84-88.
    • [51] Motta M, Imbesi R, Di Rosa M, Stivala F and Malaguarnera L. Altered plasma cytokine levels in Alzheimer's disease: correlation with the disease progression. Immunol Lett 2007; 114: 46-51.
    • [52] Stopa EG, Gonzalez AM, Chorsky R, Corona RJ, Alvarez J, Bird ED and Baird A. Basic fibroblast growth factor in Alzheimer's disease. Biochem Biophys Res Commun 1990; 171: 690-696.
    • [53] Ito S, Sawada M, Haneda M, Ishida Y and Isobe K. Amyloid-beta peptides induce several chemokine mRNA expressions in the primary microglia and Ra2 cell line via the PI3K/Akt and/or ERK pathway. Neurosci Res 2006; 56: 294-299.
    • [54] Smits HA, Rijsmus A, van Loon JH, Wat JW, Verhoef J, Boven LA and Nottet HS. Amyloid-beta-induced chemokine production in primary human macrophages and astrocytes. J Neuroimmunol 2002; 127: 160-168.
  • Inferred research data

    The results below are discovered through our pilot algorithms. Let us know how we are doing!

    Title Trust
  • No similar publications.

Share - Bookmark

Cite this article